Similar Papers

Paper Title
Journal
Date
Author
Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival.
Michael Winkelmann ... Viktoria Blumenberg
HemaSphere | VOL. 6
Michael Winkelmann, et. al.Michael Winkelmann ... Viktoria Blumenberg
01 Oct 2022
Influence of modified Lugano criteria by pre-infusion tumor kinetics on early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy.
Wolfgang G Kunz ... Jens Ricke
Journal of Clinical Oncology | VOL. 41
Wolfgang G Kunz, et. al.Wolfgang G Kunz ... Jens Ricke
01 Jun 2023
Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy
Michael Winkelmann ... Wolfgang G Kunz
Cytotherapy | VOL. 25
Michael Winkelmann, et. al.Michael Winkelmann ... Wolfgang G Kunz
11 Apr 2023
Early Prediction of Treatment Response By Circulating Tumor DNA Profiling in Patients with Diffuse Large B-Cell Lymphoma Receiving CAR T-Cell Therapy
Anna Katharina Foerster ... Florian Scherer
Blood | VOL. 142
Anna Katharina Foerster, et. al.Anna Katharina Foerster ... Florian Scherer
28 Nov 2023
View more papers

More From: Journal for ImmunoTherapy of Cancer

Paper Title
Journal
Date
Author
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Alessio Cortellini ... Biagio Ricciuti
Journal for ImmunoTherapy of Cancer | VOL. 13
Alessio Cortellini, et. al.Alessio Cortellini ... Biagio Ricciuti
04 Feb 2025
Modulating lipid metabolism improves tumor immunotherapy
Yu Ping ... Yi Zhang
Journal for ImmunoTherapy of Cancer | VOL. 13
Yu Ping, et. al.Yu Ping ... Yi Zhang
04 Feb 2025
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis
Cameron Wood ... Neal Ready
Journal for ImmunoTherapy of Cancer | VOL. 13
Cameron Wood, et. al.Cameron Wood ... Neal Ready
04 Feb 2025
Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma
Thomas Eigentler ... Ulrike Gnad-Vogt
Journal for ImmunoTherapy of Cancer | VOL. 13
Thomas Eigentler, et. al.Thomas Eigentler ... Ulrike Gnad-Vogt
04 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.